Drug Information

Drug General Information
Drug ID
D00IFR
Former ID
DNCL002111
Drug Name
AZD1208
Drug Type
Small molecular drug
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Phase 1 [532601], [542673]
Company
AstraZeneca
Structure
Download
2D MOL
Formula
C21H21N3O2S
InChI
InChI=1S/C21H21N3O2S/c22-16-9-5-11-24(13-16)19-15(12-18-20(25)23-21(26)27-18)8-4-10-17(19)14-6-2-1-3-7-14/h1-4,6-8,10,12,16H,5,9,11,13,22H2,(H,23,25,26)/b18-12-/t16-/m1/s1
InChIKey
MCUJKPPARUPFJM-UWCCDQBKSA-N
PubChem Compound ID
58423153
PubChem Substance ID
138725378, 160701269, 160866381, 163441470, 175427692, 190861995, 198990838, 210275261, 210280902, 223366031, 226088124, 227775763, 251910403, 252451606, 252470562
Target and Pathway
Target(s) Serine/threonine-proteinkinase pim-2 Target Info Modulator [532601]
KEGG Pathway Acute myeloid leukemia
NetPath Pathway IL1 Signaling Pathway
TCR Signaling Pathway
IL2 Signaling Pathway
WikiPathways Hematopoietic Stem Cell Differentiation
References
Ref 532601AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood. 2014 Feb 6;123(6):905-13.
Ref 542673(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7698).
Ref 532601AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood. 2014 Feb 6;123(6):905-13.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.